Amoxicillin-Induced Anaphylactic Shock: Pathophysiology, IgE-Mediated Mechanism, Mediators & Cardiovascular Collapse

Table of Contents

• What Is Anaphylactic Shock?
• Amoxicillin and Immediate Hypersensitivity
• Pathophysiology of Amoxicillin-Induced Anaphylaxis
• Previous Sensitization
• Re-Exposure to Amoxicillin
• Release of Anaphylactic Mediators
• Effects on Blood Vessels
• Increased Vascular Permeability and Fluid Shift
• Effects on the Respiratory System
• Cardiovascular Effects
• Development of Anaphylactic Shock
• Why Can Anaphylaxis Progress So Rapidly?
• IgE-Mediated vs Non-IgE-Mediated Reactions
• References

What Is Anaphylactic Shock?

• Anaphylactic shock is the circulatory-collapse form of anaphylaxis and represents a severe, life-threatening systemic hypersensitivity reaction.
• It is characterized by profound hypotension, reduced tissue perfusion, vascular leakage, and possible respiratory compromise.
• Anaphylactic shock can develop rapidly following exposure to a triggering substance and may progress from initial symptoms to severe cardiovascular or respiratory compromise within a short period.
• The underlying process involves the rapid activation of mast cells and basophils and the release of multiple inflammatory mediators.
• Important mediators involved in anaphylaxis include:
• Histamine
• Tryptase
• Leukotrienes
• Prostaglandins
• Platelet-activating factor (PAF)
• Cytokines and other inflammatory mediators
• These mediators produce several major physiological effects:
• Widespread vasodilation
• Increased vascular permeability
• Fluid movement from the bloodstream into tissues
• Tissue edema
• Bronchoconstriction
• Increased mucus secretion
• Airway swelling
• Widespread vasodilation reduces systemic vascular resistance, while increased vascular permeability causes loss of fluid from the intravascular compartment.
• These changes can reduce:
• Effective circulating blood volume
• Venous return
• Cardiac preload
• Cardiac output
• Blood pressure
• The resulting reduction in blood flow to organs can cause tissue hypoperfusion, which is the key hemodynamic feature of anaphylactic shock.
• Anaphylaxis can affect several organ systems simultaneously, including the:
• Cardiovascular system
• Respiratory system
• Skin and mucous membranes
• Gastrointestinal system
• Common clinical manifestations include:
• Urticaria
• Angioedema
• Wheezing
• Bronchospasm
• Stridor
• Respiratory difficulty
• Hypotension
• Dizziness
• Syncope
• Importantly, severe anaphylaxis can occur with minimal or absent skin manifestations, so the absence of urticaria does not exclude a serious reaction.
• The most dangerous complications include:
• Severe hypotension and vascular collapse
• Upper-airway obstruction
• Severe bronchospasm
• Cardiovascular dysfunction
• Reduced tissue perfusion
• In drug-induced anaphylaxis, β-lactam antibiotics are important potential triggers, making anaphylactic shock particularly relevant when discussing amoxicillin hypersensitivity.
• The classic immunological pathway is IgE-mediated type I hypersensitivity, in which antigen-specific IgE activates mast cells and basophils following exposure.
• However, anaphylaxis is not exclusively IgE-dependent. Non-IgE-mediated mechanisms, including complement activation, IgG-associated pathways, and direct mast-cell activation, can produce similar clinical manifestations.

Amoxicillin and Immediate Hypersensitivity

• Immediate hypersensitivity to amoxicillin is an acute allergic reaction that can develop rapidly after exposure, particularly in previously sensitized individuals.
• The classic mechanism is IgE-mediated type I hypersensitivity, although other immune pathways can also produce anaphylaxis-like reactions.
• Immediate reactions generally develop within minutes to approximately one hour after exposure, although the timing can vary depending on the individual, route of administration, and clinical circumstances.
• During the initial sensitization process:
• Amoxicillin or a reactive drug-derived determinant is recognized by the immune system.
• B cells are stimulated to produce amoxicillin-specific IgE antibodies.
• IgE binds to high-affinity FcεRI receptors on mast cells and basophils.
• The individual becomes sensitized to the relevant antigenic determinant.
• During subsequent exposure:
• The amoxicillin-related antigen interacts with IgE bound to mast cells and basophils.
• Cross-linking of IgE–FcεRI complexes activates these cells.
• Activated mast cells and basophils release inflammatory mediators.
• These mediators produce the clinical manifestations of immediate hypersensitivity and, in severe cases, anaphylactic shock.

Clinical Presentation

• Immediate amoxicillin hypersensitivity can range from relatively mild allergic manifestations to severe systemic anaphylaxis.
• Common manifestations include:
• Generalized urticaria
• Angioedema
• Flushing
• Itching
• Wheezing
• Bronchospasm
• Laryngeal or upper-airway edema
• Respiratory difficulty
• Hypotension
• Dizziness or syncope
• Cardiovascular collapse
• Severe reactions may involve multiple organ systems simultaneously, particularly the skin, respiratory system, and cardiovascular system.
• The presence or absence of skin manifestations does not by itself determine the severity of anaphylaxis.

Amoxicillin as an Antigenic Trigger

• The immune response to amoxicillin can involve different antigenic determinants associated with the β-lactam structure and its side chain.
• The β-lactam core can contribute to cross-reactive immune recognition among β-lactam antibiotics.
• The aminopenicillin side chain of amoxicillin can also act as an important determinant of selective hypersensitivity.
• Consequently, some individuals may demonstrate sensitivity to amoxicillin while tolerating other β-lactam antibiotics, whereas others may show broader β-lactam cross-reactivity.
• Modern allergy evaluation has therefore emphasized testing for amoxicillin-specific determinants, rather than relying exclusively on traditional penicillin determinants.

Amoxicillin-Clavulanate Reactions

• When amoxicillin is administered in combination with clavulanic acid, either component may be responsible for an immediate allergic reaction.
• Clavulanic acid can act as an independent allergenic determinant in some patients.
• This distinction is clinically important because a reaction attributed to amoxicillin-clavulanate does not necessarily mean that amoxicillin alone is responsible.

Important Diagnostic Consideration

• A reported history of “penicillin allergy” or “amoxicillin allergy” does not always indicate confirmed immediate hypersensitivity.
• Many individuals with a historical penicillin-allergy label do not demonstrate true allergy when appropriately evaluated.
• Differentiating confirmed immediate hypersensitivity from non-allergic adverse effects or non-immediate reactions is important because unnecessary avoidance of β-lactam antibiotics can affect future antimicrobial choices.
• Evaluation may involve a combination of:
• Detailed clinical history
• Skin testing
• Specific IgE testing
• Cellular assays in selected cases
• Supervised drug provocation testing when clinically appropriate

Pathophysiology of Amoxicillin-Induced Anaphylaxis

• Amoxicillin-induced anaphylaxis is a rapid, systemic hypersensitivity reaction that can affect multiple organ systems simultaneously. In classic immediate reactions, the process is primarily driven by drug-specific IgE antibodies, mast cells, and basophils.
• Amoxicillin is a low-molecular-weight β-lactam and can act as a hapten, forming antigenic determinants through interaction with host proteins. During the sensitization phase, these determinants can stimulate the production of amoxicillin-specific IgE antibodies.
• The IgE antibodies bind to high-affinity FcεRI receptors on mast cells and basophils. This sensitizes these cells without necessarily producing symptoms during the initial exposure.
• During subsequent exposure, amoxicillin-derived antigenic determinants interact with the IgE already attached to FcεRI receptors. Cross-linking of receptor-bound IgE activates the mast cell or basophil.
• FcεRI activation initiates intracellular signaling involving Lyn and Syk kinases, followed by pathways involving phospholipase C-γ (PLC-γ), phosphatidylinositol 3-kinase (PI3K), protein kinase C (PKC), and calcium signaling.
• The resulting increase in intracellular calcium promotes rapid mast-cell and basophil degranulation.
• Preformed mediators such as histamine, tryptase, chymase, and tumor necrosis factor-α (TNF-α) are released rapidly. Cellular activation also stimulates the production of newly synthesized mediators, including platelet-activating factor (PAF), prostaglandin D₂ (PGD₂), and cysteinyl leukotrienes (LTC₄, LTD₄, and LTE₄).
• These mediators act together on blood vessels, airway smooth muscle, the heart, and other tissues, producing the characteristic systemic manifestations of anaphylaxis.

Vascular and Respiratory Effects

• Histamine and other vasoactive mediators cause widespread vasodilation, reducing systemic vascular resistance.
• At the same time, increased endothelial permeability allows plasma to escape from the intravascular compartment into surrounding tissues. This produces rapid plasma extravasation and a reduction in effective circulating blood volume.
• The combination of vasodilation and intravascular fluid loss reduces venous return to the heart and can decrease cardiac output. As blood pressure falls, perfusion of vital organs becomes progressively impaired.
• Anaphylactic mediators also act on the respiratory system. Histamine and cysteinyl leukotrienes cause bronchoconstriction, increasing airway resistance and producing wheezing and breathing difficulty.
• Increased vascular permeability can cause laryngeal and upper-airway edema, potentially producing hoarseness, stridor, and airway obstruction.
• Severe bronchoconstriction, airway edema, and impaired oxygenation can further worsen the patient's condition and may occur simultaneously with cardiovascular collapse.

Cardiovascular Effects and Progression to Shock

• Cardiovascular dysfunction in anaphylaxis results from several interacting mechanisms. Systemic vasodilation decreases vascular resistance, while plasma leakage reduces effective circulating volume and venous return.
• These changes can cause severe hypotension, reduced cardiac output, and inadequate tissue perfusion.
• Anaphylactic mediators may also directly affect the myocardium and coronary circulation. In some patients, allergic mediator release can contribute to coronary vasospasm and Kounis syndrome, an acute coronary syndrome associated with hypersensitivity reactions.
• When vascular leakage, vasodilation, reduced venous return, and cardiac dysfunction become sufficiently severe, the patient develops anaphylactic shock.
• The overall sequence can be summarized as:

Amoxicillin exposure → sensitization → amoxicillin-specific IgE formation → IgE binding to FcεRI → re-exposure → IgE cross-linking → mast-cell and basophil activation → mediator release → vasodilation + vascular leakage + bronchoconstriction + cardiovascular effects → severe hypotension and tissue hypoperfusion → anaphylactic shock.

Non-IgE-Mediated Mechanisms

• Although classic immediate amoxicillin anaphylaxis is primarily associated with IgE-mediated hypersensitivity, other pathways can produce similar clinical manifestations.
• These mechanisms may involve IgG-mediated immune activation, complement activation, or direct mast-cell activation.
• The mast-cell receptor MRGPRX2 has been implicated in non-IgE-mediated drug-induced reactions. However, its importance varies between drugs, and available experimental evidence suggests that β-lactams generally have weaker direct MRGPRX2-activating activity than some other antimicrobial classes.
• Therefore, MRGPRX2-mediated activation should be considered an alternative mechanism rather than the principal pathway of classic amoxicillin anaphylaxis.
• Additional inflammatory systems, including the contact system and bradykinin generation, may further contribute to vascular permeability, vasodilation, edema, and hypotension in severe reactions.
• Following extensive mast-cell activation, temporary mast-cell hyporesponsiveness or anergy may occur because of changes in mediator stores and cellular signaling. This phenomenon has been reported after anaphylaxis but should not be interpreted as protection from future allergic reactions.

Previous Sensitization

• Previous sensitization is the immunological priming stage that prepares the immune system to respond rapidly when amoxicillin is encountered again.
• In a susceptible individual, the initial exposure to amoxicillin or its reactive drug-derived determinants can lead to recognition by the immune system without necessarily causing anaphylaxis during that first exposure.
• Because amoxicillin is a small molecule, it can act as a hapten by interacting with host proteins and forming antigenic determinants that can be recognized by the immune system.
• These determinants are processed by antigen-presenting cells and presented to T lymphocytes, promoting an immune response that can involve Th2-type signaling, B-cell activation, and production of drug-specific IgE.
• The resulting amoxicillin-specific IgE binds to high-affinity FcεRI receptors on mast cells and basophils.
• At this stage, the patient is considered sensitized. The mast cells and basophils are now armed with drug-specific IgE and can respond rapidly to a subsequent exposure.
• Importantly, sensitization does not mean that every subsequent exposure will necessarily produce anaphylaxis. The intensity of the reaction depends on factors such as the degree of sensitization, amount and route of drug exposure, and individual biological susceptibility.

Persistence and Loss of Sensitization

• Drug-specific IgE levels are not necessarily permanent. In some individuals, circulating IgE and skin-test reactivity decrease with time when there is no further exposure to the drug.
• Studies of suspected penicillin allergy have shown that measurable sensitization can decline over several years, although the rate of decline varies between individuals.
• A negative allergy test years after a previous reaction therefore does not simply mean that the original reaction was impossible; rather, immune reactivity may have waned over time.
• Conversely, previous sensitization can sometimes persist in a less readily detectable form through immunological memory.
• Re-exposure can also lead to resensitization, meaning that an individual whose detectable allergy has diminished may develop measurable allergic reactivity again after encountering the drug.
• In a study of individuals with suspected penicillin allergy, resensitization was documented after re-exposure, with a higher frequency observed among patients who had previously experienced anaphylaxis.
• This illustrates an important principle: the immune response to penicillin-class drugs can change over time, but previous allergic reactions remain clinically relevant when evaluating future exposure.

Why Previous Sensitization Matters in Anaphylaxis

• Previous sensitization explains why a person can experience a much faster and more severe reaction after re-exposure than might be expected from the initial encounter.
• During the sensitization phase:

Amoxicillin exposure → antigenic determinant formation → immune recognition → B-cell activation → amoxicillin-specific IgE production → IgE binding to FcεRI on mast cells and basophils

• During subsequent exposure:

Amoxicillin-derived antigenic determinant → cross-linking of FcεRI-bound IgE → mast-cell and basophil activation → rapid mediator release → systemic allergic reaction

• The released mediators, particularly histamine, tryptase, leukotrienes, prostaglandins, and platelet-activating factor, then produce the vascular, respiratory, and cardiovascular changes responsible for the clinical manifestations of anaphylaxis.
• Therefore, previous sensitization can be viewed as the immunological preparation stage, while re-exposure provides the trigger for rapid mast-cell and basophil activation.

Re-Exposure to Amoxicillin

• Re-exposure to amoxicillin can produce very different outcomes depending on whether the individual has a true drug hypersensitivity or only a suspected or inaccurate allergy label.
• Many individuals labeled as penicillin-allergic are subsequently found to tolerate amoxicillin during appropriately supervised evaluation.
• In genuinely sensitized individuals, however, re-exposure can trigger a rapid allergic reaction because drug-specific IgE is already present on mast cells and basophils.
• When amoxicillin-derived antigenic determinants cross-link IgE bound to FcεRI receptors, mast cells and basophils become activated and rapidly release inflammatory mediators.
• This can result in urticaria, angioedema, bronchospasm, airway edema, hypotension, and, in severe cases, anaphylactic shock.
• Therefore, re-exposure is the critical step that converts previous immunological sensitization into an active clinical reaction in classic IgE-mediated allergy.

Immune Response During Re-Exposure

• During the first sensitizing exposure, the immune system produces amoxicillin-specific IgE, which binds to FcεRI receptors on mast cells and basophils.
• On subsequent exposure, amoxicillin-derived antigenic determinants interact with these IgE molecules and promote receptor cross-linking.
• Cross-linking activates intracellular signaling pathways involving Lyn and Syk kinases, followed by calcium-dependent activation of the mast cell.
• Rapid degranulation releases preformed mediators such as histamine and tryptase, while additional mediators including leukotrienes, prostaglandins, and platelet-activating factor are generated.
• These mediators act throughout the body:
• Blood vessels: vasodilation and increased vascular permeability
• Respiratory tract: bronchoconstriction and airway edema
• Skin: urticaria, itching, and flushing
• Cardiovascular system: hypotension and reduced tissue perfusion
• If the mediator response is extensive, systemic vascular leakage and vasodilation can cause a rapid reduction in effective circulating volume and blood pressure, leading to anaphylactic shock.

Clinical Outcomes of Re-Exposure

• Controlled oral challenge studies show that a substantial proportion of patients with a suspected amoxicillin allergy do not react when formally evaluated, demonstrating why an allergy label should not automatically be considered equivalent to confirmed hypersensitivity.
• In one pediatric study involving 1,914 children with previous benign skin reactions, 94.6% tolerated a graded oral amoxicillin challenge, while 2.2% experienced mild immediate reactions and 3.2% developed delayed reactions.
• Other studies have demonstrated that longer challenge protocols can identify delayed reactions that may not become apparent after a single-day evaluation.
• In patients with confirmed non-immediate β-lactam hypersensitivity, allergic reactivity can also diminish over time, and some individuals may eventually develop clinical tolerance after prolonged avoidance.
• Conversely, patients with genuine immediate hypersensitivity remain capable of developing rapid and potentially severe reactions when re-exposed.
• Re-exposure does not always produce an immediate IgE-mediated reaction. Depending on the individual and mechanism involved, amoxicillin can also be associated with non-immediate reactions, including serum sickness-like reactions.
• Rarely, recurrent exposure has been associated with other drug-related inflammatory conditions, such as aseptic meningoencephalitis, which is mechanistically distinct from IgE-mediated anaphylaxis.
• An unusual phenomenon called mast-cell anergy has also been reported shortly after severe anaphylaxis. In this transient state, mast cells may become temporarily less responsive because of mediator depletion and changes in receptor signaling. Consequently, accidental re-exposure shortly after anaphylaxis may occasionally produce little or no immediate reaction despite persistent underlying sensitization.
• This temporary lack of symptoms does not establish that amoxicillin has become safe and should not be interpreted as protection against future reactions.

Release of Anaphylactic Mediators

• Anaphylaxis develops when activated mast cells and basophils rapidly release a combination of inflammatory, vasoactive, and bronchoconstrictive mediators.
• In classic IgE-mediated amoxicillin anaphylaxis, re-exposure to amoxicillin causes cross-linking of drug-specific IgE bound to FcεRI receptors on mast cells and basophils.
• This activates intracellular signaling pathways, increases intracellular calcium, and triggers:
• Rapid release of preformed granule mediators.
• Synthesis and release of lipid mediators.
• Production of cytokines and other inflammatory molecules.
• The combined effects of these mediators produce changes in the:
• Blood vessels.
• Respiratory tract.
• Skin.
• Gastrointestinal tract.
• Cardiovascular system.

Preformed Mediators

• Preformed mediators are already stored inside mast-cell and basophil secretory granules.
• They can therefore be released within seconds to minutes after cellular activation.
• Important preformed mediators include:

Histamine

• Produces vasodilation.
• Increases vascular permeability.
• Promotes plasma leakage into surrounding tissues.
• Contributes to urticaria, itching, flushing, and angioedema.
• Causes or contributes to bronchoconstriction and gastrointestinal smooth-muscle contraction.

Tryptase

• Is released predominantly from activated mast cells.
• Contributes to inflammatory and vascular responses.
• Serves as an important laboratory marker of mast-cell activation during suspected anaphylaxis.

Chymase and other mast-cell proteases

• Participate in local tissue and inflammatory responses.
• Can interact with extracellular proteins and plasma enzyme systems.
• May contribute to vascular and tissue changes during severe reactions.

Proteoglycans such as heparin

• Help package and stabilize mast-cell granule contents.
• Can interact with components of coagulation and contact-system pathways.

Because these mediators are preformed, their rapid release helps explain why the initial manifestations of anaphylaxis can develop very quickly after amoxicillin exposure.

Newly Synthesized Mediators

• Mast-cell activation also stimulates phospholipase pathways.
• These pathways release arachidonic acid from cell membranes and promote the production of several biologically active lipid mediators.
• Important newly synthesized mediators include:

Mediator	Major Effects During Anaphylaxis
Cysteinyl leukotrienes LTC₄, LTD₄, LTE₄	Powerful and sustained bronchoconstriction, increased airway secretions, and increased vascular permeability.
Prostaglandin D₂ PGD₂	Bronchial effects, vascular changes, and amplification of inflammatory responses.
Platelet-activating factor PAF	Increased vascular permeability, vasodilation, bronchoconstriction, and contribution to severe circulatory disturbance.
Cytokines TNF-α and IL-6	Amplification and persistence of inflammatory responses.

• Cysteinyl leukotrienes are particularly important for respiratory manifestations because they produce strong and sustained bronchoconstriction.
• PGD₂ contributes to bronchial and vascular responses.
• PAF can contribute to severe hypotension, vascular leakage, bronchoconstriction, and circulatory collapse.
• Cytokines help sustain and amplify the inflammatory response rather than producing all of the immediate manifestations by themselves.
• Human studies have demonstrated increased production of leukotrienes and PGD₂ during anaphylaxis.

How Mediators Produce Systemic Effects

• The effects of individual mediators overlap and interact with one another.
• The overall physiological response depends on the combined mediator burden rather than the action of a single molecule.
• The major sequence is:

Mast-cell/basophil activation → mediator release → vasodilation + increased vascular permeability → plasma extravasation → reduced effective circulating volume → reduced venous return → hypotension → tissue hypoperfusion → anaphylactic shock

• At the same time, respiratory effects can develop:

Mediator release → bronchoconstriction + airway edema + increased secretions → airway narrowing → impaired airflow → respiratory compromise

• These vascular and respiratory pathways can occur simultaneously.
• Severe mediator release can therefore produce both:
• Circulatory failure, through profound vasodilation and fluid loss from the circulation.
• Respiratory failure, through bronchoconstriction and upper-airway edema.

Alternative Mediator Pathways

• Although IgE–FcεRI-mediated mast-cell and basophil activation is the classic mechanism of immediate amoxicillin allergy, other pathways can contribute to anaphylaxis.
• These include:

Complement activation

• Complement fragments such as C3a and C5a can promote activation of effector cells and amplify inflammation.

IgG-mediated pathways

• IgG-dependent mechanisms have been demonstrated in experimental models of systemic anaphylaxis.
• Their contribution varies according to the triggering antigen and clinical setting.

Contact–kinin system

• Mast-cell mediators can interact with plasma contact-system pathways.
• Activation of these pathways can increase production of vasoactive kinins.

Bradykinin

• Can increase vascular permeability and contribute to edema and vascular dilation.
• It is better considered a secondary or amplifying mediator rather than the principal mediator of classic IgE-mediated amoxicillin anaphylaxis.

MRGPRX2-mediated activation

• MRGPRX2 provides a non-IgE pathway for mast-cell activation by certain drugs and other agonists.
• Its importance depends on the triggering substance.
• It should be distinguished from the classical IgE–FcεRI mechanism involved in immediate allergic reactions.

Mediator Clearance and Biomarkers

• Different anaphylactic mediators have different durations in the circulation.
• Histamine is cleared relatively rapidly, limiting its usefulness as a delayed diagnostic marker.
• Tryptase persists longer and can therefore provide laboratory evidence of mast-cell activation.
• Serum tryptase generally:
• Begins to increase after mast-cell activation.
• Commonly reaches a peak approximately 1–2 hours after symptom onset.
• Can remain detectable for several hours.
• Tryptase measurement is therefore useful as a supportive biomarker when anaphylaxis is suspected.
• However:
• A normal tryptase level does not exclude anaphylaxis.
• Tryptase release can vary between individuals and between different types of anaphylactic reactions.
• Clinical findings remain essential for diagnosis.
• Later inflammatory mediators, including cytokines, can contribute to persistence of the inflammatory response and may be associated with prolonged or delayed manifestations.

Effects on Blood Vessels

• Blood vessels are one of the major targets of anaphylactic mediators.
• During amoxicillin-induced anaphylaxis, mast-cell and basophil mediators produce rapid changes in:
• Vascular smooth-muscle tone.
• Endothelial barrier function.
• Capillary permeability.
• Intravascular blood volume.
• Systemic vascular resistance.
• These changes are central to the development of hypotension and anaphylactic shock.

Vasodilation and Reduced Vascular Resistance

• Histamine is an important mediator of acute vasodilation during anaphylaxis.
• Histamine and other vasoactive mediators act on blood vessels to cause relaxation of vascular smooth muscle and reduction in vascular tone.
• Widespread vasodilation causes:
• Decreased systemic vascular resistance.
• Expansion of the vascular compartment.
• Redistribution of blood within the circulation.
• Reduction in arterial blood pressure.
• Prostaglandin D₂ and PAF can further contribute to vascular changes during severe anaphylaxis.
• When vasodilation becomes widespread, the circulation can no longer maintain adequate arterial pressure despite compensatory cardiovascular responses.

Increased Vascular Permeability

• Anaphylactic mediators also disrupt the normal barrier function of vascular endothelial cells.
• Histamine promotes endothelial-cell contraction and formation of temporary gaps between endothelial cells, particularly in postcapillary venules.
• This increases movement of:
• Plasma water.
• Electrolytes.
• Proteins.
• Other intravascular components from the bloodstream into surrounding tissues.
• The process is known as plasma extravasation.
• Increased vascular permeability can produce:
• Tissue swelling.
• Urticaria.
• Angioedema.
• Reduction in circulating plasma volume.
• In severe systemic anaphylaxis, vascular leakage can occur across large areas of the microcirculation.

Loss of Effective Circulating Volume

• Extensive plasma leakage produces a major reduction in the effective intravascular volume.
• This does not necessarily mean that the patient's total body fluid immediately disappears; rather, a substantial portion of plasma shifts from the vascular compartment into the interstitial space.
• The resulting reduction in circulating volume causes:
• Reduced venous return to the heart.
• Reduced ventricular filling.
• Reduced preload.
• Decreased cardiac output when compensation becomes insufficient.
• Progressive hypotension.
• This combination of vasodilation and intravascular fluid loss is a major reason why anaphylaxis can progress rapidly to shock.

Endothelial Barrier Dysfunction

• The vascular endothelium normally regulates the movement of fluid and molecules between blood and tissues.
• During anaphylaxis, inflammatory mediators alter endothelial-cell junctions and increase vascular permeability.
• Histamine is particularly important during the early phase.
• Other mediators, including leukotrienes and PAF, can amplify vascular leakage and inflammatory signaling.
• Severe endothelial barrier disruption results in extensive plasma extravasation and tissue edema.
• The microvascular response therefore contributes directly to the reduction in effective circulating volume.

Effects on Blood Pressure

• Blood pressure depends largely on:
• Cardiac output.
• Systemic vascular resistance.
• Adequate circulating blood volume.
• Anaphylaxis can simultaneously disturb all three components.
• The sequence can be summarized as:

Mediator release → vasodilation → reduced systemic vascular resistance

Mediator release → increased vascular permeability → plasma extravasation → reduced effective circulating volume

Reduced venous return → reduced preload → reduced cardiac output

Reduced vascular resistance + reduced circulating volume + reduced cardiac output → severe hypotension

• When hypotension becomes severe, blood flow to vital organs becomes inadequate.
• Reduced perfusion of the brain can cause:
• Dizziness.
• Weakness.
• Confusion.
• Syncope.
• Severe and persistent reduction in tissue perfusion can progress to circulatory shock.

Vascular Changes and Anaphylactic Shock

• The vascular response is one of the central mechanisms responsible for anaphylactic shock.
• The major events occur together:

Mast-cell/basophil activation → histamine + leukotrienes + PGD₂ + PAF release → vasodilation + increased vascular permeability → plasma extravasation → reduced effective circulating volume → reduced venous return → hypotension → tissue hypoperfusion → anaphylactic shock

• The severity of shock depends on the magnitude and distribution of mediator release.
• Rapid and widespread vascular changes can overwhelm normal compensatory mechanisms.
• The result can be profound hypotension, inadequate organ perfusion, and cardiovascular collapse.

Increased Vascular Permeability and Fluid Shift

• Increased vascular permeability is a major mechanism through which anaphylactic mediators produce hypovolemia and hypotension.
• During amoxicillin-induced anaphylaxis, mediators released from activated mast cells and basophils act on the vascular endothelium.
• The resulting endothelial barrier dysfunction allows plasma to move rapidly from the intravascular space into the interstitial space.
• This process is known as plasma extravasation.
• Severe plasma leakage can produce:
• Reduced effective circulating blood volume.
• Tissue and mucosal edema.
• Reduced venous return to the heart.
• Reduced cardiac output.
• Hypotension.
• Impaired tissue perfusion.
• Anaphylactic shock.

How the Vascular Barrier Breaks Down

• The vascular barrier normally regulates the movement of water, electrolytes, proteins, and other substances between the bloodstream and surrounding tissues.
• It is maintained primarily by:
• The endothelial cell layer.
• Intercellular junctions, particularly VE-cadherin-containing adherens junctions.
• The endothelial glycocalyx.
• The underlying cytoskeleton and interactions with the extracellular matrix.
• During anaphylaxis, vasoactive mediators alter endothelial-cell signaling and junctional integrity.
• Histamine is particularly important in the early increase in vascular permeability.
• Histamine promotes endothelial-cell contraction and transient opening of intercellular gaps, particularly in postcapillary venules.
• This creates pathways through which plasma can escape into surrounding tissues.

Vascular Component	Mechanism During Anaphylaxis	Consequence
Endothelial glycocalyx	Mediator-induced endothelial injury and glycocalyx disruption	Increased permeability to fluid and plasma proteins
Adherens junctions	Alteration of VE-cadherin-mediated cell–cell adhesion	Formation of interendothelial gaps and plasma leakage
Endothelial cytoskeleton	Calcium-dependent and Rho-associated cytoskeletal contraction	Endothelial-cell retraction and increased paracellular permeability
Microvascular barrier	Combined effects of histamine, leukotrienes, PAF, and other mediators	Widespread plasma extravasation and tissue edema

Plasma Extravasation and Fluid Shift

• Under normal conditions, the endothelial barrier restricts the movement of plasma proteins into the interstitial space.
• During anaphylaxis, this barrier becomes significantly more permeable.
• Plasma containing water, electrolytes, and proteins moves from the circulation into surrounding tissues.
• The fluid shift can occur rapidly because anaphylactic mediator release is systemic.
• The sequence can be summarized as:

Mast-cell/basophil activation → mediator release → endothelial barrier disruption → increased vascular permeability → plasma extravasation → reduced intravascular volume

• The leaked fluid contributes to interstitial and tissue edema.
• When leakage is extensive, the vascular compartment becomes relatively underfilled even though total body fluid has not necessarily been lost externally.

Reduction in Effective Circulating Volume

• Extensive plasma leakage reduces the amount of fluid effectively available within the circulation.
• This produces a form of relative hypovolemia.
• The reduction in circulating volume leads to:
• Reduced venous return.
• Reduced ventricular filling.
• Reduced preload.
• Reduced cardiac output when compensatory mechanisms become inadequate.
• Progressive hypotension.
• At the same time, widespread vasodilation further increases the capacity of the vascular system.
• Therefore, anaphylaxis can produce both:
• Relative hypovolemia from plasma leakage.
• Reduced systemic vascular resistance from widespread vasodilation.

Tissue and Organ Edema

• Increased vascular permeability causes fluid accumulation within tissues.
• Clinically, this can produce:
• Urticaria from fluid accumulation in the superficial dermis.
• Angioedema from deeper tissue swelling.
• Upper-airway edema, which can compromise airflow.
• Gastrointestinal wall edema, which can contribute to abdominal symptoms.
• Excessive vascular leakage in the lungs can contribute to pulmonary interstitial edema and impaired gas exchange in severe systemic reactions.
• Edema therefore contributes not only to visible swelling but also to potentially serious respiratory and circulatory complications.

Relationship Between Fluid Shift and Hypotension

• The relationship between vascular permeability and blood pressure can be represented as:

Increased vascular permeability → plasma leakage → reduced effective circulating volume → reduced venous return → reduced cardiac output → hypotension

• At the same time:

Anaphylactic mediators → systemic vasodilation → reduced systemic vascular resistance → further fall in blood pressure

• These mechanisms reinforce one another.
• Reduced blood pressure decreases tissue perfusion.
• Reduced tissue perfusion can impair oxygen delivery to vital organs.
• If severe hypotension persists, the patient can progress from anaphylaxis to anaphylactic shock.

Interaction With Respiratory Complications

• Vascular permeability also contributes to airway swelling.
• Increased endothelial permeability in the upper respiratory tract allows fluid to accumulate in surrounding tissues.
• This can cause:
• Lip and tongue swelling.
• Pharyngeal edema.
• Laryngeal edema.
• Progressive upper-airway obstruction.
• At the same time, leukotrienes and histamine can cause bronchoconstriction.
• Therefore, anaphylaxis can produce respiratory compromise through two major mechanisms:

Airway edema + bronchoconstriction → narrowing of the airway → impaired airflow → respiratory distress

Effects on the Respiratory System

• The respiratory system is one of the major organ systems affected during amoxicillin-induced anaphylaxis. Following re-exposure in a sensitized individual, activation of mast cells and basophils causes the rapid release of histamine, cysteinyl leukotrienes, prostaglandin D₂, platelet-activating factor (PAF), and other inflammatory mediators. These mediators act on the upper and lower airways, producing bronchoconstriction, mucosal edema, increased airway secretions, and upper-airway obstruction.
• Respiratory compromise may develop rapidly and can become a major contributor to life-threatening anaphylaxis.

Bronchoconstriction

• Cysteinyl leukotrienes, particularly LTC₄, LTD₄, and LTE₄, are potent bronchoconstrictors released during mast-cell activation.
• Histamine and prostaglandin D₂ can further increase airway smooth-muscle contraction and contribute to narrowing of the bronchial lumen.
• Bronchoconstriction increases airway resistance and reduces airflow, producing wheezing, chest tightness, coughing, and difficulty breathing.
• Severe bronchoconstriction can markedly impair ventilation and contribute to hypoxemia.
• Patients with underlying airway hyperreactivity may experience more pronounced bronchospasm during anaphylaxis.

Upper-Airway Edema and Obstruction

• Increased vascular permeability caused by histamine and other mediators allows plasma to move from the intravascular compartment into surrounding tissues.
• When this process occurs in the larynx, pharynx, and other upper-airway structures, tissue swelling can develop rapidly.
• Angioedema of the tongue, lips, pharynx, and larynx can narrow the upper airway.
• Laryngeal edema may produce hoarseness, a sensation of throat tightness, stridor, difficulty swallowing, and progressive airway obstruction.
• Severe upper-airway edema can become life-threatening because even a relatively small reduction in airway diameter can substantially increase resistance to airflow.

Increased Airway Secretions and Mucosal Swelling

• Histamine and cysteinyl leukotrienes can stimulate airway secretions and contribute to mucosal swelling.
• Increased mucus production, together with bronchoconstriction and mucosal edema, further narrows the airway lumen.
• The combined effects can significantly impair ventilation, particularly when bronchospasm is severe.

Impaired Gas Exchange

• Severe bronchoconstriction creates ventilation abnormalities by reducing airflow to affected regions of the lungs.
• Airway edema and mucus accumulation can produce additional ventilation-perfusion mismatch.
• As respiratory compromise progresses, oxygen delivery to tissues may decrease, resulting in hypoxemia.
• In severe anaphylaxis, respiratory failure can develop alongside profound circulatory abnormalities.

Respiratory Contribution to Anaphylactic Shock

Respiratory and cardiovascular abnormalities can reinforce each other during severe anaphylaxis:

Mast-cell and basophil activation

↓

Histamine, leukotrienes, PGD₂, PAF and other mediator release

↓

Bronchoconstriction + airway mucosal edema + increased secretions

↓

Airway narrowing and impaired ventilation

↓

Hypoxemia and respiratory distress

At the same time:

Vasodilation + increased vascular permeability

↓

Plasma extravasation and reduced effective circulating volume

↓

Reduced venous return and hypotension

↓

Reduced tissue perfusion and oxygen delivery

Thus, severe anaphylaxis can produce both respiratory failure and circulatory shock. Hypoxemia from airway compromise occurs alongside impaired tissue perfusion caused by hypotension, increasing the risk of organ dysfunction.

Why Respiratory Symptoms Can Develop Rapidly

The rapid onset of respiratory symptoms is primarily related to the immediate release of preformed and newly synthesized mast-cell mediators following immune-cell activation.

• Histamine promotes bronchial effects, vascular permeability, and mucosal edema.
• Cysteinyl leukotrienes produce potent and sustained bronchoconstriction and increase airway secretions.
• Prostaglandin D₂ contributes to bronchial and vascular responses.
• PAF contributes to bronchoconstriction, vascular permeability, and severe systemic cardiovascular disturbance.
• The combined effects can produce substantial airway narrowing within a short period.

The respiratory manifestations of amoxicillin-induced anaphylaxis therefore arise primarily from acute mediator-driven airway narrowing and tissue edema, rather than from the chronic inflammatory remodeling mechanisms associated with environmental respiratory diseases.

Cardiovascular Effects

• The cardiovascular system is a major target of systemic mediator release during amoxicillin-induced anaphylaxis. Following re-exposure in a sensitized individual, mast cells and basophils release histamine, platelet-activating factor (PAF), prostaglandin D₂, leukotrienes, and other mediators that produce widespread vascular and cardiac effects.
• Profound vasodilation is one of the earliest cardiovascular consequences. Histamine and other mediators relax vascular smooth muscle, producing widespread arteriolar and venous dilation. This decreases systemic vascular resistance (SVR) and expands the functional vascular space, contributing to a rapid reduction in arterial blood pressure.
• Venodilation also reduces the amount of blood returning to the heart. At the same time, mediator-induced endothelial permeability allows plasma to move from the intravascular compartment into surrounding tissues. This plasma extravasation produces a reduction in effective circulating blood volume.
• The combination of vasodilation and plasma leakage produces relative hypovolemia, resulting in reduced venous return and ventricular filling. Reduced preload can decrease stroke volume and cardiac output, particularly when vascular leakage is severe.
• The cardiovascular sequence can therefore be summarized as:
• Mediator release → vasodilation + increased vascular permeability → plasma extravasation → reduced effective circulating volume → reduced venous return → reduced preload → reduced cardiac output → hypotension.
• Severe hypotension decreases perfusion of vital organs. When arterial pressure falls substantially, the brain, kidneys, heart, and other tissues may receive inadequate blood flow, resulting in dizziness, weakness, syncope, altered consciousness, and tissue hypoperfusion.
• The heart can also be affected by the consequences of systemic anaphylaxis. Reduced venous return limits cardiac filling, while severe hypotension can decrease coronary perfusion pressure. Respiratory involvement may produce hypoxemia, further increasing myocardial stress.
• In severe reactions, inflammatory and vasoactive mediators may contribute to myocardial dysfunction. Platelet-activating factor and other mediators have been implicated in cardiovascular depression during anaphylaxis, although the relative contribution of individual mediators can vary between patients.
• Cardiac arrhythmias may occur during severe anaphylaxis, particularly when hypotension, hypoxemia, myocardial ischemia, or metabolic disturbances are present. Treatment-related effects can also influence cardiac rhythm, but epinephrine remains the first-line treatment for anaphylaxis because prompt administration is essential for reversing airway, vascular, and cardiovascular compromise.
• Anaphylaxis can occasionally produce coronary vasospasm and acute myocardial ischemia through mast-cell and mediator-mediated effects on the coronary circulation. This phenomenon is associated with Kounis syndrome, which describes acute coronary manifestations occurring in the setting of an allergic or hypersensitivity reaction. Its presentation can range from transient coronary spasm to myocardial infarction.
• Cardiovascular and respiratory abnormalities can reinforce each other during severe anaphylaxis. Bronchoconstriction and upper-airway edema can cause impaired ventilation and hypoxemia, while vasodilation and plasma leakage cause hypotension and reduced tissue perfusion. Together, reduced oxygenation and reduced circulation can markedly impair tissue oxygen delivery.
• The progression toward cardiovascular collapse can be summarized as:

Amoxicillin re-exposure

↓

IgE-mediated mast-cell and basophil activation

↓

Release of histamine, leukotrienes, PGD₂, PAF, and other mediators

↓

Vasodilation + increased vascular permeability

↓

Reduced systemic vascular resistance + plasma extravasation

↓

Reduced effective circulating volume

↓

Reduced venous return and preload

↓

Reduced cardiac output + severe hypotension

↓

Reduced tissue perfusion

↓

Organ hypoperfusion and anaphylactic shock

Development of Anaphylactic Shock

• Anaphylactic shock represents the severe cardiovascular form of systemic anaphylaxis in which widespread mediator release causes profound vasodilation, increased vascular permeability, reduced effective circulating volume, and impaired tissue perfusion. In amoxicillin-induced anaphylaxis, these changes can develop rapidly following re-exposure in a sensitized individual.
• The process begins when amoxicillin-derived antigenic determinants cross-link IgE antibodies bound to FcεRI receptors on mast cells and basophils. This activates intracellular signaling pathways and triggers rapid degranulation together with the synthesis and release of additional lipid mediators and cytokines.
• The released mediators, particularly histamine, cysteinyl leukotrienes, prostaglandin D₂, platelet-activating factor (PAF), and other vasoactive substances, act on the vascular system. Histamine and other mediators produce widespread vasodilation, reducing systemic vascular resistance and causing blood to pool within the expanded vascular compartment.
• At the same time, inflammatory mediators increase microvascular endothelial permeability. Plasma moves from the intravascular space into surrounding tissues, producing plasma extravasation and tissue edema. This rapidly reduces the effective circulating blood volume, creating a state of relative hypovolemia.
• The combination of vasodilation and plasma leakage produces a characteristic hemodynamic sequence:

Systemic mediator release

↓

Vasodilation + increased vascular permeability

↓

Reduced systemic vascular resistance + plasma extravasation

↓

Reduced effective circulating volume

↓

Reduced venous return

↓

Reduced ventricular preload

↓

Reduced stroke volume and cardiac output

↓

Severe hypotension

↓

Tissue hypoperfusion

↓

Anaphylactic shock

• Reduced venous return is particularly important because venodilation and intravascular fluid loss decrease the amount of blood available to return to the heart. Reduced ventricular filling lowers preload and can subsequently reduce stroke volume and cardiac output.
• As arterial pressure falls, perfusion of vital organs becomes compromised. The brain may receive insufficient blood flow, producing dizziness, weakness, confusion, or syncope. Severe and persistent hypotension can progress to widespread tissue hypoperfusion and dysfunction of multiple organs.
• The body initially attempts to compensate through sympathetic activation, increasing heart rate and vascular tone to preserve arterial pressure. However, when mediator-induced vasodilation and fluid redistribution are sufficiently severe, these compensatory mechanisms may become inadequate.
• Nitric oxide (NO) can contribute to the profound vasodilation observed during anaphylaxis. Experimental evidence indicates that endothelial nitric oxide synthase (eNOS)-derived NO participates in the vascular hyporeactivity associated with severe anaphylactic shock. This pathway contributes to loss of vascular tone but should be considered one component of a broader mediator-driven process rather than the sole mechanism.
• Platelet-activating factor (PAF) can further intensify cardiovascular dysfunction by increasing vascular permeability, promoting vasodilation, and contributing to reduced blood pressure. Its effects may interact with other inflammatory mediators during severe anaphylaxis.
• Activation of the contact-kinin system may also contribute to vascular permeability and hypotension through generation of bradykinin. This represents an additional pathway that can amplify vascular responses but is not the principal mechanism of classic IgE-mediated amoxicillin anaphylaxis.
• Anaphylaxis can also occur through non-IgE-mediated pathways, including complement activation, IgG-associated mechanisms, and direct activation of mast cells through receptors such as MRGPRX2. These pathways are relevant to the broader biology of anaphylaxis, although classic immediate amoxicillin allergy is primarily associated with IgE-mediated mast-cell and basophil activation.
• Several factors can influence the severity of anaphylaxis. β-adrenergic blockers and other cardiovascular medications, underlying mast-cell disorders, and certain concurrent conditions or exposures may modify the clinical response or make treatment more difficult. These factors should be regarded as potential severity modifiers rather than direct causes of anaphylactic shock.
• Respiratory and cardiovascular abnormalities can occur simultaneously. Bronchoconstriction and upper-airway edema can impair ventilation and oxygenation, while vasodilation and plasma extravasation reduce tissue perfusion. The combination of hypoxemia and reduced circulating oxygen delivery can further worsen organ dysfunction.
• In severe cases, myocardial involvement may occur. Profound hypotension can reduce coronary perfusion, while inflammatory mediators and hypoxemia may increase myocardial stress. Coronary vasospasm and acute myocardial ischemia, including manifestations associated with Kounis syndrome, can occur in some patients.
• The progression to shock can therefore be viewed as a failure of the cardiovascular system to compensate for the combined effects of vascular dilation, endothelial barrier disruption, intravascular fluid loss, and impaired cardiac filling.

Why Can Anaphylaxis Progress So Rapidly?

Anaphylaxis can progress within minutes because mast cells and basophils can release potent mediators almost immediately after activation. In classic amoxicillin-induced anaphylaxis, previous sensitization allows amoxicillin-derived antigenic determinants to cross-link drug-specific IgE bound to high-affinity FcεRI receptors on mast cells and basophils. This rapidly initiates cellular signaling, degranulation, and the production of additional inflammatory mediators.

• Rapid mast-cell and basophil activation: Cross-linking of FcεRI-bound IgE activates intracellular signaling pathways and promotes rapid degranulation. Preformed mediators such as histamine, tryptase, chymase, and other granule components can therefore be released within minutes.
• Immediate action of preformed mediators: Histamine acts rapidly on blood vessels and airway smooth muscle. It promotes vasodilation and increased vascular permeability, while also contributing to bronchoconstriction and mucosal swelling. These effects can occur simultaneously rather than sequentially.
• Amplification by newly generated mediators: Mast-cell activation is followed by production of lipid mediators such as cysteinyl leukotrienes, prostaglandin D₂, and platelet-activating factor (PAF). These mediators can prolong and amplify bronchoconstriction, vascular leakage, vasodilation, and cardiovascular dysfunction.
• Simultaneous involvement of multiple organ systems: Anaphylaxis does not depend on damage to a single organ. Mediators act on the vascular, respiratory, gastrointestinal, and cardiovascular systems at approximately the same time. Consequently, airway narrowing may develop alongside vascular leakage and hypotension, allowing clinical deterioration to occur very quickly.
• Rapid loss of effective circulating volume: Increased vascular permeability causes plasma to move from the intravascular space into surrounding tissues. When combined with widespread vasodilation, this rapidly decreases venous return and preload, contributing to severe hypotension and impaired tissue perfusion.
• Respiratory compromise can develop concurrently: Cysteinyl leukotrienes, histamine, and other mediators can produce bronchoconstriction, while increased vascular permeability contributes to edema of the upper airway. This combination can rapidly impair airflow and oxygenation.
• Limited time for compensation: The cardiovascular system initially attempts to compensate through sympathetic activation, including tachycardia and increased vascular tone. However, extensive vasodilation and plasma extravasation can overwhelm these compensatory mechanisms, resulting in progressive hypotension and shock.
• Alternative pathways can contribute: Not all anaphylactic reactions are exclusively IgE-mediated. Complement activation, IgG-dependent mechanisms, and direct mast-cell activation have been described in anaphylaxis. However, these pathways should be regarded as alternative mechanisms rather than the principal explanation for classic IgE-mediated amoxicillin anaphylaxis.
• Host factors can modify severity: The clinical course may be influenced by factors such as cardiovascular disease, respiratory disease, mast-cell disorders, concomitant medications, and the route of drug administration. These factors can affect the ability of the body to compensate for the rapid hemodynamic and respiratory changes.
• The overall sequence is extremely rapid:

Amoxicillin re-exposure → IgE–FcεRI cross-linking → mast-cell/basophil activation → mediator release → vasodilation + vascular leakage + bronchoconstriction → reduced venous return and impaired oxygenation → hypotension and tissue hypoperfusion → anaphylactic shock.

IgE-Mediated vs Non-IgE-Mediated Reactions

Amoxicillin-induced immediate hypersensitivity can occur through different immunological pathways. The classic mechanism is IgE-mediated type I hypersensitivity, in which amoxicillin-derived antigenic determinants cross-link drug-specific IgE bound to FcεRI on mast cells and basophils. Other immediate reactions can occur through non-IgE mechanisms, including complement activation, IgG-dependent pathways, or direct mast-cell activation. These mechanisms can converge on mast-cell and basophil mediator release and therefore produce clinically similar manifestations, including urticaria, angioedema, bronchospasm, hypotension, and anaphylactic shock.

• IgE-mediated reaction: During sensitization, amoxicillin-derived antigenic determinants promote production of amoxicillin-specific IgE. The IgE binds high-affinity FcεRI receptors on mast cells and basophils. On subsequent exposure, antigenic determinants cross-link receptor-bound IgE, triggering intracellular signaling, calcium mobilization, degranulation, and mediator release.
• Non-IgE-mediated reaction: Some immediate hypersensitivity reactions occur without detectable drug-specific IgE. Potential mechanisms include complement activation with generation of anaphylatoxins such as C3a and C5a, IgG-dependent activation of Fcγ receptors, and direct activation of mast cells through receptors such as MRGPRX2.
• MRGPRX2-mediated activation: MRGPRX2 is expressed on human mast cells and can respond directly to certain drugs and other cationic compounds. This mechanism can produce rapid mast-cell activation without the adaptive IgE sensitization required for classical allergy. However, MRGPRX2 should not be presented as the principal mechanism of classic amoxicillin-induced anaphylaxis; its importance varies according to the drug and clinical context.
• Differences in sensitization: A classical IgE-mediated reaction generally requires previous immune sensitization, although the sensitizing exposure may not have been recognized by the patient. Non-IgE mechanisms can occur without detectable allergen-specific IgE and, depending on the mechanism, may occur during an initial clinically recognized exposure.
• Differences in cellular activation: IgE-mediated activation is initiated through FcεRI cross-linking, whereas non-IgE reactions may activate mast cells or other effector cells through different receptors or inflammatory pathways. Despite these differences at the molecular level, both pathways can ultimately produce rapid release of histamine, tryptase, leukotrienes, prostaglandins, PAF, and other mediators.
• Clinical manifestations can overlap: Both IgE-mediated and non-IgE-mediated anaphylaxis can cause flushing, urticaria, angioedema, bronchoconstriction, upper-airway edema, gastrointestinal symptoms, hypotension, and cardiovascular collapse. Therefore, the clinical presentation alone does not reliably establish the underlying molecular mechanism.
• Laboratory testing has limitations: Elevated serum tryptase can support a diagnosis of systemic mast-cell activation but does not by itself determine whether activation was IgE-dependent or non-IgE-dependent. Similarly, a negative test for drug-specific IgE does not necessarily exclude an immediate hypersensitivity reaction because currently available tests do not identify every relevant pathway.
• Diagnosis of amoxicillin allergy requires clinical context: A history of the timing of symptoms, previous exposure, clinical manifestations, route of administration, and other potential causes is important. Depending on the reaction history, specialist evaluation may include skin testing, laboratory investigations, and a supervised drug challenge when considered appropriate.
• The distinction matters for future drug use: Confirming whether a patient has a genuine amoxicillin allergy is important because an inaccurate β-lactam allergy label can unnecessarily restrict antibiotic choices. Conversely, a patient with a convincing history of immediate amoxicillin anaphylaxis requires appropriate specialist assessment before considering future exposure.

Feature	IgE-mediated reaction	Non-IgE-mediated reaction
Primary trigger	Amoxicillin-derived antigenic determinant recognized by drug-specific IgE	Complement, IgG/Fcγ receptors, direct mast-cell activation, or other pathways
Key mast-cell receptor	FcεRI	May involve MRGPRX2 or other pathways
Previous sensitization	Usually required for classical allergy	Not necessarily required
Mast-cell activation	IgE–FcεRI cross-linking	Receptor-dependent or mediator-dependent activation
Major mediators	Histamine, tryptase, leukotrienes, PGD₂, PAF, and others	Similar downstream mediators can be released
Clinical presentation	Can produce rapid systemic anaphylaxis	Can produce clinically similar immediate reactions
Role in classic amoxicillin anaphylaxis	Principal established mechanism	Alternative mechanisms; importance depends on the specific reaction
Diagnostic challenge	Drug-specific IgE may not always be detectable	No single routine test identifies all non-IgE mechanisms

The most important distinction for this article is that classic amoxicillin-induced anaphylactic shock is primarily an IgE–FcεRI-mediated process, whereas non-IgE pathways provide additional mechanisms through which mast-cell activation and anaphylaxis can occur. Regardless of the initiating pathway, once widespread mediator release occurs, the downstream physiological effects—vasodilation, increased vascular permeability, bronchoconstriction, hypotension, and impaired tissue perfusion—can converge and produce anaphylactic shock.

References

• Alvarez-Arango, S., Kumar, M., Chow, T. G., & Sabato, V. (2024). Non-IgE-mediated immediate drug-induced hypersensitivity reactions. The Journal of Allergy and Clinical Immunology: In Practice, 12, 1109–1119. https://doi.org/10.1016/j.jaip.2024.02.019
• Bakshi, D., Tang, X., & Waserman, S. (2024). A case of pediatric serum sickness-like reaction after a 2-month re-exposure to amoxicillin. Allergy, Asthma & Clinical Immunology, 20. https://doi.org/10.1186/s13223-024-00887-7
• Blanca-López, N., Pérez-Alzate, D., Ruano, F., Garcimartín, M., Torre, V. D. L., Mayorga, C., Somoza, M. L., Perkins, J., Blanca, M., Canto, M. G., & Torres, M. E. (2015). Selective immediate responders to amoxicillin and clavulanic acid tolerate penicillin derivative administration after confirming the diagnosis. Allergy, 70, 1013–1019. https://doi.org/10.1111/all.12636
• Brown, S. (2007). The pathophysiology of shock in anaphylaxis. Immunology and Allergy Clinics of North America, 27(2), 165–175. https://doi.org/10.1016/j.iac.2007.03.003
• Bruhns, P., & Chollet-Martin, S. (2021). Mechanisms of human drug-induced anaphylaxis. The Journal of Allergy and Clinical Immunology, 147(4), 1133–1142. https://doi.org/10.1016/j.jaci.2021.02.013
• Bykov, Y. V. (2026). Contemporary concepts of anaphylaxis pathogenesis. Fundamental and Clinical Medicine. https://doi.org/10.23946/2500-0764-2026-11-2-28-37
• Cauwels, A., Janssen, B., Buys, E., Sips, P., & Brouckaert, P. (2006). Anaphylactic shock depends on PI3K and eNOS-derived NO. The Journal of Clinical Investigation, 116(8), 2244–2251. https://doi.org/10.1172/JCI25426
• Cianferoni, A. (2021). Non-IgE-mediated anaphylaxis. The Journal of Allergy and Clinical Immunology, 147(4), 1123–1131. https://doi.org/10.1016/j.jaci.2021.02.012
• Confino-Cohen, R., Rosman, Y., Lachover, I., & Goldberg, A. (2016). The importance of amoxicillin and amoxicillin-clavulanate determinants in the diagnosis of immediate allergic reactions to β-lactams. International Archives of Allergy and Immunology, 170, 62–66. https://doi.org/10.1159/000446961
• Doña, I., Guidolin, L., Bogas, G., Olivieri, E., Labella, M., Schiappoli, M., Dama, A., Salas, M., Senna, G., Bonadonna, P., & Torres, M. (2022). Resensitization in suspected penicillin allergy. Allergy, 78, 214–224. https://doi.org/10.1111/all.15508
• Ebo, D., Beyens, M., Heremans, K., et al. (2022). Recent knowledge and insights on the mechanisms of immediate hypersensitivity and anaphylaxis: IgE/FcεRI- and non-IgE/FcεRI-dependent. Current Pharmaceutical Design. https://doi.org/10.2174/1381612829666221025091827
• Esteban, V., Skrabski, F., Perales-Chordá, C., Puente-Crespo, Y., Muñoz-Cano, R., & Cardona, V. (2025). Perspectives in the molecular mechanisms underlying anaphylaxis. Journal of Investigational Allergology and Clinical Immunology. https://doi.org/10.18176/jiaci.1080
• Exius, R., Gabrielli, S., Abrams, E., et al. (2021). Establishing amoxicillin allergy in children through direct graded oral challenge: Evaluating risk factors for positive challenges, safety, and risk of cross-reactivity to cephalosporins. The Journal of Allergy and Clinical Immunology: In Practice. https://doi.org/10.1016/j.jaip.2021.06.057
• Fernández-Bravo, S., Palacio-García, L., Requena-Robledo, N., Yuste-Montalvo, A., Nuñez-Borque, E., & Esteban, V. (2022). Anaphylaxis: mediators, biomarkers and microenvironments. Journal of Investigational Allergology & Clinical Immunology. https://doi.org/10.18176/jiaci.0854
• Fetarayani, D., Kahdina, M., Sandra, D. Y., & Sutanto, H. (2025). Drug-induced anaphylaxis: Molecular pathophysiology, diagnosis, and management. Asia Pacific Allergy, 16, 181–197. https://doi.org/10.5415/apallergy.0000000000000233
• Finkelman, F., Khodoun, M., & Strait, R. (2016). Human IgE-independent systemic anaphylaxis. The Journal of Allergy and Clinical Immunology, 137, 1674–1680. https://doi.org/10.1016/j.jaci.2016.02.015
• Ghebrehiwet, B., Joseph, K., & Kaplan, A. P. (2024). The bradykinin-forming cascade in anaphylaxis and ACE-inhibitor induced angioedema/airway obstruction. Frontiers in Allergy, 5. https://doi.org/10.3389/falgy.2024.1302605
• Guilarte, M., Sala-Cunill, A., Luengo, O., Labrador-Horrillo, M., & Cardona, V. (2017). The mast cell, contact, and coagulation system connection in anaphylaxis. Frontiers in Immunology, 8. https://doi.org/10.3389/fimmu.2017.00846
• Guyénard, L., Tauber, M., Debord-Peguet, S., Bérard, F., Nosbaum, A., Hacard, F., Castells, M., & Nicolas, J. (2024). Case report: Mast cell anergy: absence of symptoms after accidental re-exposure to amoxicillin/clavulanic acid 3 days after anaphylaxis. Frontiers in Allergy, 5. https://doi.org/10.3389/falgy.2024.1366922
• Hellenthal, K. E. M., Brabenec, L., & Wagner, N.-M. (2022). Regulation and dysregulation of endothelial permeability during systemic inflammation. Cells, 11. https://doi.org/10.3390/cells11121935
• Kounis, N., Soufras, G., & Hahalis, G. (2013). Anaphylactic shock: Kounis hypersensitivity-associated syndrome seems to be the primary cause. North American Journal of Medical Sciences, 5, 631–636. https://doi.org/10.4103/1947-2714.122304
• Krzysztof, P., & Andrzej, T. (2023). Platelet-activating factor as an endogenous cofactor of food anaphylaxis. BioFactors, 49, 976–983. https://doi.org/10.1002/biof.1956
• Kumar, P., Shen, Q., Pivetti, C., Lee, E. S., Wu, M. H., & Yuan, S. Y. (2009). Molecular mechanisms of endothelial hyperpermeability: implications in inflammation. Expert Reviews in Molecular Medicine, 11, e19. https://doi.org/10.1017/S1462399409001112
• Labrosse, R., Paradis, L., Lacombe-Barrios, J., et al. (2018). Efficacy and safety of 5-day challenge for the evaluation of nonsevere amoxicillin allergy in children. The Journal of Allergy and Clinical Immunology: In Practice, 6(5), 1673–1680. https://doi.org/10.1016/j.jaip.2018.01.030
• Mali, S. B., & Jambure, R. (2012). Anaphylaxis management: Current concepts. Anesthesia, Essays and Researches, 6, 115–123. https://doi.org/10.4103/0259-1162.108284
• Montañez, M., Mayorga, C., Bogas, G., Barrionuevo, E., Fernández-Santamaría, R., Martin-Serrano, Á., Laguna, J., Torres, M., Fernandez, T., & Doña, I. (2017). Epidemiology, mechanisms, and diagnosis of drug-induced anaphylaxis. Frontiers in Immunology, 8, 614. https://doi.org/10.3389/fimmu.2017.00614
• Moon, C. T., Befus, A., Kulka, M., & Lacy, P. (2014). Mast cell mediators: their differential release and the secretory pathways involved. Frontiers in Immunology, 5. https://doi.org/10.3389/fimmu.2014.00569
• Muñoz Bellido, F. J., García, M. G. T., García, C. M., & Dávila, I. J. (2022). Changes in sensitization patterns in the last 25 years in 619 patients with confirmed diagnoses of immediate hypersensitivity reactions to beta-lactams. Biomedicines, 10. https://doi.org/10.3390/biomedicines10071535
• Muñoz-Cano, R., Pascal, M., Araujo, G., Goikoetxea, M. J., Valero, A., Picado, C., & Bartra, J. (2017). Mechanisms, cofactors, and augmenting factors involved in anaphylaxis. Frontiers in Immunology, 8, 1193. https://doi.org/10.3389/fimmu.2017.01193
• Nagy, J. A., Benjamin, L., Zeng, H., Dvorak, A. M., & Dvorak, H. F. (2008). Vascular permeability, vascular hyperpermeability and angiogenesis. Angiogenesis, 11, 109–119. https://doi.org/10.1007/s10456-008-9099-z
• Nakamura, T., & Murata, T. (2018). Regulation of vascular permeability in anaphylaxis. British Journal of Pharmacology, 175, 2538–2542. https://doi.org/10.1111/bph.14332
• Nguyen, S., Rupprecht, C., Haque, A., Pattanaik, D., Yusin, J., & Krishnaswamy, G. (2021). Mechanisms governing anaphylaxis: Inflammatory cells, mediators, endothelial gap junctions and beyond. International Journal of Molecular Sciences, 22. https://doi.org/10.3390/ijms22157785
• Nuñez-Borque, E., Fernández-Bravo, S., Yuste-Montalvo, A., & Esteban, V. (2022). Pathophysiological, cellular, and molecular events of the vascular system in anaphylaxis. Frontiers in Immunology, 13, 836222. https://doi.org/10.3389/fimmu.2022.836222
• Ono, E., Taniguchi, M., Mita, H., et al. (2009). Increased production of cysteinyl leukotrienes and prostaglandin D₂ during human anaphylaxis. Clinical & Experimental Allergy, 39. https://doi.org/10.1111/j.1365-2222.2008.03104.x
• Ono, S., Egawa, G., & Kabashima, K. (2017). Regulation of blood vascular permeability in the skin. Inflammation and Regeneration, 37. https://doi.org/10.1186/s41232-017-0042-9
• Pałgan, K. (2023). Mast cells and basophils in IgE-independent anaphylaxis. International Journal of Molecular Sciences, 24. https://doi.org/10.3390/ijms241612802
• Pastorello, E., Stafylaraki, C., Mirone, C., et al. (2015). Anti-amoxicillin immunoglobulin E, histamine-2 receptor antagonist therapy and mast cell activation syndrome are risk factors for amoxicillin anaphylaxis. International Archives of Allergy and Immunology, 166, 280–286. https://doi.org/10.1159/000380950
• Pillinger, N., & Kam, P. (2017). Endothelial glycocalyx: basic science and clinical implications. Anaesthesia and Intensive Care, 45, 295–307. https://doi.org/10.1177/0310057X1704500305
• Piotin, A., Godet, J., Trubiano, J., et al. (2021). Predictive factors of amoxicillin immediate hypersensitivity and validation of PEN-FAST clinical decision rule. Annals of Allergy, Asthma & Immunology. https://doi.org/10.1016/j.anai.2021.07.005
• Reber, L. L., Hernandez, J. D., & Galli, S. J. (2017). The pathophysiology of anaphylaxis. The Journal of Allergy and Clinical Immunology, 140, 335–348. https://doi.org/10.1016/j.jaci.2017.06.003
• Romano, A., Atanasković-Marković, M., Barbaud, A., et al. (2020). Towards a more precise diagnosis of hypersensitivity to beta-lactams—an EAACI position paper. Allergy, 75, 1300–1315. https://doi.org/10.1111/all.14122
• Saravi, B., Goebel, U., Hassenzahl, L. O., Jung, C., David, S., Feldheiser, A., Stopfkuchen-Evans, M., & Wollborn, J. (2023). Capillary leak and endothelial permeability in critically ill patients: a current overview. Intensive Care Medicine Experimental, 11. https://doi.org/10.1186/s40635-023-00582-8
• Shenoy, E. S., Macy, E., Rowe, T., & Blumenthal, K. G. (2019). Evaluation and management of penicillin allergy: A review. JAMA, 321, 188–199. https://doi.org/10.1001/jama.2018.19283
• Shi, Q., Wang, S., Wang, G., et al. (2024). Serum metabolomics analysis reveals potential biomarkers of penicillins-induced fatal anaphylactic shock in rats. Scientific Reports, 14. https://doi.org/10.1038/s41598-024-74623-x
• Stevens, W., Kraft, M., & Eisenbarth, S. (2023). Recent insights into the mechanisms of anaphylaxis. Current Opinion in Immunology, 81, 102288. https://doi.org/10.1016/j.coi.2023.102288
• Torres, M., & Blanca, M. (2010). The complex clinical picture of beta-lactam hypersensitivity: Penicillins, cephalosporins, monobactams, carbapenems, and clavams. Medical Clinics of North America, 94(4), 805–820. https://doi.org/10.1016/j.mcna.2010.04.006
• Torres, M. J., Zambonino, M., Corzo, J., et al. (2014). Diagnostic evaluation of hypersensitivity reactions to beta-lactam antibiotics in a large population of children. Pediatric Allergy and Immunology, 25, 80–87. https://doi.org/10.1111/pai.12155
• Torres-Rojas, I., De La Torre, V. M., Pérez-Alzate, D., et al. (2025). Children with confirmed nonimmediate allergic reactions to beta-lactam antibiotics can develop tolerance after a long period of drug avoidance. Pediatric Allergy and Immunology, 36. https://doi.org/10.1111/pai.70184
• Torres-Rojas, I., Pérez-Alzate, D., Somoza, M. L., et al. (2023). Clavulanic acid is a leading culprit beta-lactam in immediate allergic reactions to penicillins. Allergy, Asthma & Immunology Research, 15, 201–213. https://doi.org/10.4168/aair.2023.15.2.201
• Triggiani, M., Patella, V., Granata, F., & Marone, G. (2008). Allergy and the cardiovascular system. Clinical & Experimental Immunology, 153. https://doi.org/10.1111/j.1365-2249.2008.03714.x
• Wakasugi, R., Suzuki, K., & Kaneko-Kawano, T. (2024). Molecular mechanisms regulating vascular endothelial permeability. International Journal of Molecular Sciences, 25. https://doi.org/10.3390/ijms25126415
• Wang, X., Kennard, L., Rutkowski, K., et al. (2022). Amoxicillin hypersensitivity: Patient outcomes in a seven-year retrospective study. Annals of Allergy, Asthma & Immunology. https://doi.org/10.1016/j.anai.2022.06.021
• Worm, M., Pazur, K., Morakabati, P., & Redhu, D. (2025). IgE and non-IgE-mediated pathways in anaphylaxis. Seminars in Immunopathology, 47. https://doi.org/10.1007/s00281-025-01056-7
• Zagursky, R. J., & Pichichero, M. E. (2017). Cross-reactivity in β-lactam allergy. The Journal of Allergy and Clinical Immunology: In Practice, 6(1), 72–81.e1. https://doi.org/10.1016/j.jaip.2017.08.027
• Zhang, T., Che, D., Liu, R., et al. (2017). Typical antimicrobials induce mast cell degranulation and anaphylactoid reactions via MRGPRX2 and its murine homologue MRGPRB2. European Journal of Immunology, 47. https://doi.org/10.1002/eji.201746951